← Back to Search

Nightmare Reduction Techniques for Narcolepsy

N/A
Waitlist Available
Led By Jennifer Mundt, PhD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of study (11-13 weeks)
Awards & highlights
No Placebo-Only Group

Summary

This trial will test two treatments to reduce nightmares in narcolepsy patients. Participants will log sleep symptoms & complete questionnaires & a sleep study.

Who is the study for?
Adults with narcolepsy who often have nightmares (at least 3 times a week) can join this study. They must be stable on sleep and psychiatric meds for 3 months, speak English, live in the US, and be able to visit Evanston, IL for appointments. Those already in psychotherapy or with previous nightmare treatments cannot participate.
What is being tested?
The trial is testing if imagery rehearsal therapy (IRT) helps reduce nightmares in people with narcolepsy and if adding targeted dream control (TDC) improves results. Participants will track their sleep, attend treatment sessions, fill out questionnaires, and some will do a sleep study nap.
What are the potential side effects?
Since the interventions are behavioral therapies like IRT and TDC rather than medications, they may not have typical side effects but could include temporary increases in nightmare frequency or distress due to focusing on dreams during treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of study (11-13 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of study (11-13 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Daily diary

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Imagery rehearsal therapy and targeted dream control (IRT+TDC)Experimental Treatment2 Interventions
Participants randomized to this group will receive 7 sessions of IRT+TDC.
Group II: Imagery rehearsal therapy (IRT)Experimental Treatment1 Intervention
Participants randomized to this group will receive 7 sessions of IRT.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imagery rehearsal therapy
2023
N/A
~10
Targeted dream control
2023
N/A
~10

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,640 Previous Clinical Trials
957,565 Total Patients Enrolled
3 Trials studying Narcolepsy
135 Patients Enrolled for Narcolepsy
Jennifer Mundt, PhDPrincipal InvestigatorNorthwestern University
1 Previous Clinical Trials
60 Total Patients Enrolled
1 Trials studying Narcolepsy
60 Patients Enrolled for Narcolepsy

Media Library

Imagery rehearsal therapy Clinical Trial Eligibility Overview. Trial Name: NCT05709873 — N/A
Narcolepsy Research Study Groups: Imagery rehearsal therapy (IRT), Imagery rehearsal therapy and targeted dream control (IRT+TDC)
Narcolepsy Clinical Trial 2023: Imagery rehearsal therapy Highlights & Side Effects. Trial Name: NCT05709873 — N/A
Imagery rehearsal therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05709873 — N/A
~3 spots leftby Nov 2025